Celltrion Pharm, Inc. (068760.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	578.0B	536.4B	477.8B	388.8B	386.0B
Cost of Revenue	404.3B	375.4B	355.8B	269.1B	274.4B
Gross Profit	173.7B	161.0B	122.0B	119.7B	111.7B
Operating Expenses
R&D Expense	16.8B	19.1B	13.0B	12.7B	8.0B
SG&A Expense	31.9B	41.9B	31.9B	35.2B	34.5B
General & Admin Expense	6.0B	7.6B	6.6B	6.1B	4.8B
Selling & Marketing Expense	25.9B	34.3B	25.3B	29.0B	29.7B
Other Expenses	71.8B	43.9B	39.9B	35.8B	31.0B
Total Operating Expenses	111.7B	104.9B	84.8B	83.6B	73.5B
Cost and Expenses	516.0B	480.3B	440.6B	352.7B	347.9B
Operating Income (EBIT)	62.0B	56.1B	37.2B	36.1B	38.2B
Non-Operating
Interest Income	2.8B	2.6B	1.6B	1.3B	1.1B
Interest Expense	6.3B	6.7B	7.5B	8.3B	6.2B
Net Interest Income	(3.5B)	(4.1B)	(5.9B)	(7.0B)	(5.1B)
Other Non-Op Income/Expense	(6.1B)	(6.4B)	(7.5B)	(9.9B)	(7.7B)
Non-Operating Income (excl Interest)	1.0B	—	(41.8M)	1.6B	1.5B
EBT (Pre-Tax Income)	56.0B	49.7B	29.8B	26.2B	30.5B
Income Tax Expense	13.1B	11.0B	7.8B	4.9B	4.5B
Bottom Line
Net Income	42.9B	38.8B	22.0B	21.3B	26.0B
Earnings from Cont. Ops	42.9B	38.8B	22.0B	21.3B	26.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	42.9B	38.8B	22.0B	21.3B	26.0B
Per Share
Basic EPS	₩970	₩892	₩521	₩479	₩585
Diluted EPS	₩970	₩892	₩520	₩479	₩584
Revenue Per Share	₩12,972	₩12,350	₩10,994	₩8,933	₩9,321
Shares
Basic Shares Outstanding	44.6M	43.4M	43.5M	43.5M	41.4M
Diluted Shares Outstanding	44.6M	43.4M	43.5M	43.5M	41.5M
Profitability Metrics
EBITDA	86.1B	78.4B	57.4B	54.2B	54.1B
D&A	23.5B	22.3B	20.1B	19.7B	17.4B
EBIT	62.7B	56.1B	37.3B	34.5B	36.7B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026